On the Activity Enhancing Role of Iron Oxide for Noble Metal Oxidation Catalysts: A CVD-Based Study with Differently Structured Combinations of Pt and FeOₓ Coatings on Al₂O₃

With regard to the catalysis of oxidation reactions by noble metals, the addition of FeOx to an Al2O3-supported Pt catalyst is known to be energetically more favorable compared to only Pt. In this work, different process routes for the preparation of such Fe-promoted Pt/Al2O3 catalysts via atmospheric chemical vapor deposition (CVD) in a fluidized bed were explored. Specifically, the question of whether it would be advantageous to deposit the Fe before, along with, or after the Pt was addressed, and new information was obtained about the optimum FeOx–Pt interface and mixing ratio. Vapors of Trimethyl(methylcyclopentadienyl)platinum(IV) and/or Ethyl-ferrocene were injected into the bed from the top, permitting a quasi-lossless precursor operation and a very good control of the deposited metal, and hence of the catalyst structure. Samples could be extracted from the top while CVD was ongoing to obtain time-resolved data. The catalytic activity was determined through CO oxidation. The Fe-Pt mixing ratio was then varied for the most active deposition sequence, in order to identify an activity optimum generated by the minimum amount of Pt catalyst. When compared to pure Pt/Al2O3, the optimum catalyst consistently showed superior performance even after thermal stres

The PROVENT-C19 registry: A study protocol for international multicenter SIAARTI registry on the use of prone positioning in mechanically ventilated patients with COVID-19 ARDS

Background The worldwide use of prone position (PP) for invasively ventilated patients with COVID-19 is progressively increasing from the first pandemic wave in everyday clinical practice. Among the suggested treatments for the management of ARDS patients, PP was recommended in the Surviving Sepsis Campaign COVID-19 guidelines as an adjuvant therapy for improving ventilation. In patients with severe classical ARDS, some authors reported that early application of prolonged PP sessions significantly decreases 28-day and 90-day mortality. Methods and analysis Since January 2021, the COVID19 Veneto ICU Network research group has developed and implemented nationally and internationally the "PROVENT-C19 Registry", endorsed by the Italian Society of Anesthesia Analgesia Resuscitation and Intensive Care. . .'(SIAARTI). The PROVENT-C19 Registry wishes to describe 1. The real clinical practice on the use of PP in COVID-19 patients during the pandemic at a National and International level; and 2. Potential baseline and clinical characteristics that identify subpopulations of invasively ventilated patients with COVID-19 that may improve daily from PP therapy. This web-based registry will provide relevant information on how the database research tools may improve our daily clinical practice. Conclusions This multicenter, prospective registry is the first to identify and characterize the role of PP on clinical outcome in COVID-19 patients. In recent years, data emerging from large registries have been increasingly used to provide real-world evidence on the effectiveness, quality, and safety of a clinical intervention. Indeed observation-based registries could be effective tools aimed at identifying specific clusters of patients within a large study population with widely heterogeneous clinical characteristics. Copyright

On the Activity Enhancing Role of Iron Oxide for Noble Metal Oxidation Catalysts: A CVD-Based Study with Differently Structured Combinations of Pt and FeOx Coatings on Al2O3

With regard to the catalysis of oxidation reactions by noble metals, the addition of FeOx to an Al2O3-supported Pt catalyst is known to be energetically more favorable compared to only Pt. In this work, different process routes for the preparation of such Fe-promoted Pt/Al2O3 catalysts via atmospheric chemical vapor deposition (CVD) in a fluidized bed were explored. Specifically, the question of whether it would be advantageous to deposit the Fe before, along with, or after the Pt was addressed, and new information was obtained about the optimum FeOx–Pt interface and mixing ratio. Vapors of Trimethyl(methylcyclopentadienyl)platinum(IV) and/or Ethyl-ferrocene were injected into the bed from the top, permitting a quasi-lossless precursor operation and a very good control of the deposited metal, and hence of the catalyst structure. Samples could be extracted from the top while CVD was ongoing to obtain time-resolved data. The catalytic activity was determined through CO oxidation. The Fe-Pt mixing ratio was then varied for the most active deposition sequence, in order to identify an activity optimum generated by the minimum amount of Pt catalyst. When compared to pure Pt/Al2O3, the optimum catalyst consistently showed superior performance even after thermal stress

On the Activity Enhancing Role of Iron Oxide for Noble Metal Oxidation Catalysts: A CVD-Based Study with Differently Structured Combinations of Pt and FeOx Coatings on Al2O3

With regard to the catalysis of oxidation reactions by noble metals, the addition of FeOx to an Al2O3-supported Pt catalyst is known to be energetically more favorable compared to only Pt. In this work, different process routes for the preparation of such Fe-promoted Pt/Al2O3 catalysts via atmospheric chemical vapor deposition (CVD) in a fluidized bed were explored. Specifically, the question of whether it would be advantageous to deposit the Fe before, along with, or after the Pt was addressed, and new information was obtained about the optimum FeOx–Pt interface and mixing ratio. Vapors of Trimethyl(methylcyclopentadienyl)platinum(IV) and/or Ethyl-ferrocene were injected into the bed from the top, permitting a quasi-lossless precursor operation and a very good control of the deposited metal, and hence of the catalyst structure. Samples could be extracted from the top while CVD was ongoing to obtain time-resolved data. The catalytic activity was determined through CO oxidation. The Fe-Pt mixing ratio was then varied for the most active deposition sequence, in order to identify an activity optimum generated by the minimum amount of Pt catalyst. When compared to pure Pt/Al2O3, the optimum catalyst consistently showed superior performance even after thermal stress

Correction: Pasin et al. On the Activity Enhancing Role of Iron Oxide for Noble Metal Oxidation Catalysts: A CVD-Based Study with Differently Structured Combinations of Pt and FeO<em>_x</em> Coatings on Al₂O₃. <em>Coatings</em> 2018, <em>8</em>, 217

In the original version of article [...

Post-anaesthesia pulmonary complications after use of muscle relaxants (POPULAR): a multicentre, prospective observational study

Background Results from retrospective studies suggest that use of neuromuscular blocking agents during general anaesthesia might be linked to postoperative pulmonary complications. We therefore aimed to assess whether the use of neuromuscular blocking agents is associated with postoperative pulmonary complications. Methods We did a multicentre, prospective observational cohort study. Patients were recruited from 211 hospitals in 28 European countries. We included patients (aged ≥18 years) who received general anaesthesia for any in-hospital procedure except cardiac surgery. Patient characteristics, surgical and anaesthetic details, and chart review at discharge were prospectively collected over 2 weeks. Additionally, each patient underwent postoperative physical examination within 3 days of surgery to check for adverse pulmonary events. The study outcome was the incidence of postoperative pulmonary complications from the end of surgery up to postoperative day 28. Logistic regression analyses were adjusted for surgical factors and patients’ preoperative physical status, providing adjusted odds ratios (ORadj) and adjusted absolute risk reduction (ARRadj). This study is registered with ClinicalTrials.gov, number NCT01865513. Findings Between June 16, 2014, and April 29, 2015, data from 22803 patients were collected. The use of neuromuscular blocking agents was associated with an increased incidence of postoperative pulmonary complications in patients who had undergone general anaesthesia (1658 [7·6%] of 21694); ORadj 1·86, 95% CI 1·53–2·26; ARRadj –4·4%, 95% CI –5·5 to –3·2). Only 2·3% of high-risk surgical patients and those with adverse respiratory profiles were anaesthetised without neuromuscular blocking agents. The use of neuromuscular monitoring (ORadj 1·31, 95% CI 1·15–1·49; ARRadj –2·6%, 95% CI –3·9 to –1·4) and the administration of reversal agents (1·23, 1·07–1·41; –1·9%, –3·2 to –0·7) were not associated with a decreased risk of postoperative pulmonary complications. Neither the choice of sugammadex instead of neostigmine for reversal (ORadj 1·03, 95% CI 0·85–1·25; ARRadj –0·3%, 95% CI –2·4 to 1·5) nor extubation at a train-of-four ratio of 0·9 or more (1·03, 0·82–1·31; –0·4%, –3·5 to 2·2) was associated with better pulmonary outcomes. Interpretation We showed that the use of neuromuscular blocking drugs in general anaesthesia is associated with an increased risk of postoperative pulmonary complications. Anaesthetists must balance the potential benefits of neuromuscular blockade against the increased risk of postoperative pulmonary complications